SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: luis a. garcia who wrote (788)1/4/1998 3:18:00 AM
From: joco  Read Replies (2) | Respond to of 1115
 
luis:
I have a real problem with Bristol Meyers not renewing the liscense.
If Lidacol can make a distributor truck loads of money, then why on
earth would BM let this great deal go to another company. I have to make a decision before the market opens Monday if it is worth hanging on to LDAKA. Why would BM not renew the liscense, there
is a reason and that really bothers me.

THANKS joco



To: luis a. garcia who wrote (788)1/6/1998 12:18:00 AM
From: telebob  Read Replies (1) | Respond to of 1115
 
luis,
thanks for the reply.
Lidak said they would publish the data in a journal. I called invest relations and they dont have a publishing timeframe . I dont think the aborted outbreak
resulkts showed statistical significance.
I think the risk reward is positive now, anyway.
good luck,


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News